The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases
Authors
Keywords
-
Journal
Immunotherapy
Volume 13, Issue 6, Pages 527-539
Publisher
Future Medicine Ltd
Online
2021-03-15
DOI
10.2217/imt-2020-0230
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report
- (2020) Yasuki Hijikata et al. INTERNAL MEDICINE
- Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies
- (2019) Christopher C. Frohne et al. Journal for ImmunoTherapy of Cancer
- Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
- (2019) Alessio Cortellini et al. ONCOLOGIST
- Immune checkpoint inhibitor use in antisynthetase syndrome
- (2019) David Mackintosh et al. Asia-Pacific Journal of Clinical Oncology
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
- (2019) Anne Zaremba et al. Journal for ImmunoTherapy of Cancer
- Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus
- (2019) Marco Tagliamento et al. Immunotherapy
- Immunotherapy-induced severe neutropenia with neurotoxicity: A case of a 75-year-old woman with ulcerative colitis diagnosed with melanoma
- (2019) Rima Patel et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis
- (2019) Takahiro Yamada et al. INTERNAL MEDICINE
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
- (2018) Katharina C. Kähler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report
- (2018) Kenta Ogawa et al. INVESTIGATIONAL NEW DRUGS
- Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
- (2018) Giulia C. Leonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer
- (2018) Rohan Garje et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab treatment associated with myasthenic crises and unfavorable disease course
- (2018) Eda Derle et al. NEUROLOGICAL SCIENCES
- Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab
- (2018) Kanako Sakurai et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
- (2018) Michael D. Richter et al. Arthritis & Rheumatology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Mécanismes physiopathologiques des effets secondaires des immunothérapies par anticorps anti-CTLA-4, anti-PD-1 et anti-PD-L1 dans le traitement du cancer
- (2018) Tilda Passat et al. BULLETIN DU CANCER
- Pembrolizumab for the first-line treatment of non-small cell lung cancer
- (2018) Kiichiro Ninomiya et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PD-1 Inhibitor Immune-Related Adverse Events in Patients with Preexisting Endocrine Autoimmunity
- (2018) Halis Kaan Akturk et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Rapid Development of Graves’ Ophthalmopathy After Treatment With Ipilimumab and Recurrence With Pembrolizumab in a Patient With Previously Treated Graves’ Disease
- (2018) Logan Rhea et al. Journal of Oncology Practice
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis
- (2017) Akshjot Puri et al. MELANOMA RESEARCH
- Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
- (2017) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge
- (2017) M. Kostine et al. REVUE DE MEDECINE INTERNE
- Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma
- (2016) N Matsumura et al. ACTA DERMATO-VENEREOLOGICA
- Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced Non–Small Cell Lung Cancer: A Case Report
- (2016) Konstantinos Syrigos et al. ANNALS OF INTERNAL MEDICINE
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
- (2016) B. Lee et al. ANNALS OF ONCOLOGY
- Vasculitic neuropathy induced by pembrolizumab
- (2016) F. Aya et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
- (2016) Leonard Calabrese et al. ANNALS OF THE RHEUMATIC DISEASES
- Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
- (2016) Marc Uemura et al. Journal of Hematology & Oncology
- Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non–Small Cell Lung Cancer (NSCLC)
- (2016) Puey Ling Chia et al. JOURNAL OF IMMUNOTHERAPY
- Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease
- (2016) Lara V. Maul et al. JOURNAL OF IMMUNOTHERAPY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
- (2016) K. H. Vincent Lau et al. MUSCLE & NERVE
- Myasthenia gravis exacerbation associated with pembrolizumab
- (2016) Julia Zhu et al. MUSCLE & NERVE
- Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
- (2016) Michiel van der Vlist et al. Nature Reviews Rheumatology
- Pembrolizumab (Keytruda)
- (2016) Gerry Kwok et al. Human Vaccines & Immunotherapeutics
- Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated With Pembrolizumab
- (2016) Philipp Roberts et al. JAMA Ophthalmology
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
- (2016) Kristen M. Beck et al. Journal for ImmunoTherapy of Cancer
- Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
- (2016) Michael Ong et al. Journal for ImmunoTherapy of Cancer
- Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
- (2015) Tomohiko Narita et al. JOURNAL OF DERMATOLOGY
- Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma
- (2015) Y. Kato et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
- (2015) Jennifer A. Lo et al. JAMA Oncology
- Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
- (2015) A Doran Bostwick et al. Journal for ImmunoTherapy of Cancer
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
- (2014) Magnus Pedersen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ipilimumab in a patient with known Crohn's disease: To give or not to give?
- (2014) Eric A.R. Gielisse et al. Journal of Crohns & Colitis
- Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
- (2014) Edward J Gettings et al. Multiple Sclerosis Journal
- Ipilimumab in patients with melanoma and autoimmune disease
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Updated assessment of the prevalence, spectrum and case definition of autoimmune disease
- (2012) Scott M. Hayter et al. AUTOIMMUNITY REVIEWS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started